Patents by Inventor Michael R. Kozlowski

Michael R. Kozlowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7071231
    Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 4, 2006
    Assignee: Telik, Inc.
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
  • Patent number: 7029695
    Abstract: Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: April 18, 2006
    Assignee: Telik, Inc.
    Inventors: Thomas Redelmeier, Lawrence M. Kauvar, Robert T. Lum, Matthew H. Lyttle, Robert W. Macsata, Steven R. Schow, Hugo O. Villar, Michael R. Kozlowski
  • Patent number: 6653321
    Abstract: Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds. These compounds, as single stereoisomers or mixtures of stereoisomers, or their pharmaceutically acceptable salts, are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: November 25, 2003
    Assignee: Telik, Inc.
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum, Louise Robinson, Jeong Weon Park
  • Publication number: 20030135063
    Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Application
    Filed: September 6, 2002
    Publication date: July 17, 2003
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V.V.S.V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
  • Publication number: 20030100511
    Abstract: Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.
    Type: Application
    Filed: July 10, 2001
    Publication date: May 29, 2003
    Inventors: Lawrence M. Kauvar, Robert T. Lum, Matthew H. Lyttle, Robert W. Macsata, Steven R. Schow, Hugo O. Villar, Michael R. Kozlowski
  • Patent number: 6506739
    Abstract: Bis-(N,N′-bis-(2-haloethyl)amino)phosphoramidates, pharmaceutical compositions containing them, methods of treatment using them, and processes for their preparation. The compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of cancer.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: January 14, 2003
    Assignee: Telik, Inc.
    Inventors: R. Jason Herr, Robert T. Lum, Steven R. Schow, Fanying Meng, Michael R. Kozlowski, Pavel Zhichkin
  • Patent number: 6458998
    Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: October 1, 2002
    Assignee: Telik, Inc.
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
  • Patent number: 6337338
    Abstract: Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: January 8, 2002
    Assignee: Telik, Inc.
    Inventors: Michael R. Kozlowski, Robert T. Lum, Steven R. Schow, Hugo O. Villar, Micheal M. Wick
  • Patent number: 6274738
    Abstract: The invention provides DNA primase assays suitable for identifying DN primase modulating agents, methods of modulating DNA primase activity, compounds for modulating DNA primase activity, and compositions which modulate DNA primase.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: August 14, 2001
    Assignee: Geron Corporation
    Inventors: Michael R. Kozlowski, Junko Aimi, Ryan Holcomb
  • Patent number: 6083713
    Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: July 4, 2000
    Assignees: Bristol-Myers Squibb Company, McLean Hospital Corporation
    Inventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
  • Patent number: 5854392
    Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.
    Type: Grant
    Filed: August 30, 1993
    Date of Patent: December 29, 1998
    Assignees: Bristol-Myers Squibb Company, McLean Hospital Corporation
    Inventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
  • Patent number: 5834193
    Abstract: Methods and compositions for the measurement of telomere length have application in medical diagnostic, prognostic, and therapeutic procedures. The methods for measuring telomere length include primer extension-based methods and probe-based methods. The primer extension methods involve elongation of telomeric, linker, and/or subtelomeric based primers under conditions such that the telomere serves as a template for primer extension and that the resultant primer extension products can be compared to standards of known length to provide a measure of telomere length. The probe based methods allow for telomere length measurements using DNA from lysed or whole cells and involve hybridizing an excess of probe to all telomeric repeat sequences in the telomere, measuring the amount of bound probe, and correlating the amount of bound probe measured with telomere length.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 10, 1998
    Assignee: Geron Corporation
    Inventors: Michael R. Kozlowski, Karen R. Prowse, Sy-Shi Wang, Sharon Wong, Nam Woo Kim, Richard Allsopp
  • Patent number: 5760062
    Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of pyrido?b!thiophenes, pyrido?b!furans, pyridine ethers or pyridine thioethers. Such compounds are characterized by the following structure: ##STR1## X.sub.3 is oxygen or sulfur; and the double dashed lines between X.sub.4 and X.sub.5 indicate an optional double bond, which, when present, forms a fused, bicyclic pyrido?b!furan or pyrido?b!thiophene ring system, depending upon whether X.sub.3 is oxygen or sulfur, respectively. When the double bond is not present, the compound is a monocyclic pyridine ether or thioether, again depending upon whether X.sub.3 is oxygen or sulfur. X.sub.4 is --CH.sub.2 R.sub.21 or --CR.sub.21 --, where R.sub.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 2, 1998
    Assignee: Geron Corporation
    Inventors: Federico C.A. Gaeta, Adam A. Galan, Michael R. Kozlowski, Karen R. Prowse, Elaine C. Stracker, Patricia A. Peterli-Roth
  • Patent number: 5741677
    Abstract: Methods are provided for the determination of telomere length. These methods can be used for diagnosis of cancer and the staging of cancer, and diagnosis of senecesence in cells. Also, the instant methods can be used to determine stages of diseases such as atherosclerosis or HIV infection, and can be used to diagnose infertility.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 21, 1998
    Assignee: Geron Corporation
    Inventors: Michael R. Kozlowski, Karen R. Prowse, Sy-shi Wang, Sharon Wong, Nam Woo Kim, Richard Allsop
  • Patent number: 5332574
    Abstract: Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities.
    Type: Grant
    Filed: February 11, 1993
    Date of Patent: July 26, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Koko Sugawara, Koji Tomita, Michael R. Kozlowski, Yosuke Sawada